Beta

Ascentage pharma group internationalAAPG.US Overview

US StockHealthcare
(No presentation for AAPG)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

AAPG AI Insights

AAPG Overall Performance

AAPG AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AAPG Recent Performance

-1.58%

Ascentage pharma group international

-1.10%

Avg of Sector

-0.49%

S&P500

AAPG PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check AAPG's Trend

AAPG Key Information

AAPG Valuation Metrics

AAPG Profile

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Price of AAPG

AAPG FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AAPG Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-52.96
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.89
PB Ratio
11.52
Price-to-FCF
2.31
METRIC
VALUE
vs. INDUSTRY
Gross Margin
84.09%
Net Margin
-216.74%
Revenue Growth (YoY)
-42.10%
Profit Growth (YoY)
-49.82%
3-Year Revenue Growth
-6.74%
3-Year Profit Growth
-13.09%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-52.96
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.89
PB Ratio
11.52
Price-to-FCF
2.31
Gross Margin
84.09%
Net Margin
-216.74%
Revenue Growth (YoY)
-42.10%
Profit Growth (YoY)
-49.82%
3-Year Revenue Growth
-6.74%
3-Year Profit Growth
-13.09%

  • When is AAPG's latest earnings report released?

    The most recent financial report for Ascentage pharma group international (AAPG) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AAPG's short-term business performance and financial health. For the latest updates on AAPG's earnings releases, visit this page regularly.

  • What is the operating profit of AAPG?

    According to the latest financial report, Ascentage pharma group international (AAPG) reported an Operating Profit of -640.85M with an Operating Margin of -191.8% this period, representing a decline of 13.07% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is AAPG's revenue growth?

    In the latest financial report, Ascentage pharma group international (AAPG) announced revenue of 334.13M, with a Year-Over-Year growth rate of 112.95%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does AAPG have?

    As of the end of the reporting period, Ascentage pharma group international (AAPG) had total debt of 1.98B, with a debt ratio of 0.5. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does AAPG have?

    At the end of the period, Ascentage pharma group international (AAPG) held Total Cash and Cash Equivalents of 2.47B, accounting for 0.62 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does AAPG go with three margins increasing?

    In the latest report, Ascentage pharma group international (AAPG) did not achieve the “three margins increasing” benchmark, with a gross margin of 79.44%%, operating margin of -191.8%%, and net margin of -191.53%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess AAPG's profit trajectory and future growth potential.

  • Is AAPG's EPS continuing to grow?

    According to the past four quarterly reports, Ascentage pharma group international (AAPG)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -6.92. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.